GlassScriptPhysician profile
Laura R Pearson
NPI 1366461162
$3,391.73
in general payments reported to CMS, 2019-2025
35 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $178 · 2021: $510 · 2022: $529 · 2023: $898 · 2024: $462 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vector Surgical, LLC | $522.05 | 2019-2025 | |
| Exelixis INC. | $446.34 | 2023-2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $320.00 | 2021-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $267.78 | 2019-2025 | |
| Daiichi Sankyo INC. | $232.82 | 2021-2025 | Enhertu |
| Elucent Medical | $224.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.56 | 2021-2025 | Tagrisso |
| Seagen INC. | $137.75 | 2021-2023 | Adcetris |
| Hologic INC | $115.70 | 2022 | |
| Glaxosmithkline, LLC. | $111.70 | 2021-2023 | Ojjaara |
| Genentech USA, INC. | $102.70 | 2023-2024 | Venclexta, Tecentriq, Alecensa |
| Regeneron Healthcare Solutions, INC. | $86.92 | 2021-2023 | Libtayo |
| Amgen INC. | $80.51 | 2019-2022 | |
| Leica Microsystems INC. | $68.06 | 2022-2023 | Neoprobe |
| E.R. Squibb & Sons, L.L.C. | $57.10 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $54.89 | 2025 | Zoladex |
| Sumitomo Pharma America, INC. | $42.79 | 2025 | Orgovyx |
| Focal Therapeutics, INC. | $28.17 | 2020 | |
| Polynovo North America LLC | $25.38 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.28 | 2024 | Pedmark |
| Jazz Pharmaceuticals INC. | $22.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.51 | 2022 | |
| Clovis Oncology, INC. | $21.45 | 2020 | |
| Macrogenics, INC. | $19.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.10 | 2022 | |
| Bard Peripheral Vascular, INC. | $18.22 | 2020 | |
| Beone Medicines USA, INC. | $17.92 | 2025 | Tevimbra |
| Karyopharm Therapeutics INC. | $17.67 | 2022 | |
| Hologic Sales and Service, LLC | $16.13 | 2025 | Magseed |
| Ipsen Biopharmaceuticals, INC | $15.21 | 2020 | |
| Baxter Healthcare | $14.69 | 2021 | |
| Kyowa Kirin, INC. | $14.54 | 2020 | |
| Kci USA, INC. | $13.69 | 2023 | Prevena Restor Bellaform, Prevena |
| Mallinckrodt Hospital Products INC. | $13.06 | 2020 | |
| Dysis Medical, INC. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.